Mod GRF 1-29 & Ipamorelin Blend (10mg)


Size: 10mg
Contents: CJC-1295 NO DAC (Mod GRF 1-29) 5mg, Ipamorelin 5mg
Form: Lyophilized powder
Purity: >99%

FREE Shipping on $200+ orders

FREE Bacteriostatic Water (30ml) on $200+ orders

Discount per Quantity

5 - 85%$75.05
9 +10%$71.10
SKU: P-MODGRFIPAM-10 Categories: , Tags: ,


Mod GRF 1-29 & Ipamorelin Peptide Blend

The Ipamorelin peptide has been studied for its potential as a synthetic analog of growth hormone (hGH) and is composed of five amino acids. Modified GRF (1-29) peptide, also known as Mod GRF 1-29, is a synthetic analog of endogenous growth hormone-releasing hormones (GHRH). Composed of 29 amino acids, it has few modifications compared to the endogenous GHRH – it has four amino groups that more stable groups substitute – hence it is named a modified GRF 1-29.(1)

These peptides may possibly stimulate the pituitary gland and trigger the release of growth hormones. When presented together as a blend, these peptides appear to yield more synergistic results. They may produce additional potential action such as anti-aging activity, improved bone density, better sleep cycle, and overall positive impact on intestine and cardiac health.

The key potential of this peptide blend may be that Ipamorelin appears to be a fast-acting peptide with a short half-life, whereas Mod GRF 1-29 may have longer-lasting impacts. So when taken together, the action of Ipamorelin begin faster, and soon as it starts to wean off the action of Mod GRF 1-29 peptide may kick in – yielding potentially longer-lasting results.

Chemical Makeup (1) (2) (3)

Molecular formula: Modified GRF 1-29 peptide: C152H252N44O42, Ipamorelin: C38H49N9O(5)
Molecular weight: Modified GRF 1-29 peptide: 3367.9 g/mol, Ipamorelin: 711.9 g/mol
Other known titles: Modified GRF 1-29 peptide: CJC 1295 Without DAC, Mod GRF (1-29). Ipamorelin: Ipamorelin Acetate, IPA

Research and Clinical Studies

Mod GRF 1-29 & Ipamorelin Blend and GSHs, GHRPs

Both Mod GRF 1-29 and Ipamorelin peptides belong to the class of growth hormone secretagogues (GSHs). One study(4) examined the potential of growth hormone secretagogues (GSHs) and growth hormone-releasing peptides (GHRPs) in a clinical setting. Several test subjects presented with GSHs were monitored for any physiological changes. As an outcome of this rigorous study, it was suggested that these peptides appeared to improve growth rates in younger subjects, increase appetite, and improve lean mass in older subjects. In obese test models, these peptides were observed to stimulate a reduction in bone turnover, increase lean mass, and improve sleep cycle.  As per this study, these peptides “increase lean body mass, reduce fat mass, increase exercise tolerance and maximum oxygen uptake, enhance muscle strength, and improve linear growth. Long-term studies of GH administration offer conflicting results regarding its safety, which has led to strict FDA criteria for GH use.”(4)

Mod GRF 1-29 & Ipamorelin Blend General Research

A 1998 study(5) was carried out where these growth hormone secretagogues were presented in the rat pituitary gland as well as in anesthetized rats and conscious swine. Results of all three studies suggested that these peptides are agonists of GHRP-like receptors, as they bind to these receptors and help secrete higher concentrations of growth hormone. While some growth hormone secretagogues also appeared to trigger increased levels of other hormones such as cortisol and ACTH, Ipamorelin and Modified GRF 1-29 peptides appeared to exhibit selectivity towards growth hormones only, suggesting that these peptides may be particular in their functions.

In one 1999 clinical study,(6) 8 male subjects were enrolled to examine the potential of growth hormone secretagogues at different concentrations. The concentrations were increased every 15 minutes for up to two hours. After the study was completed, the concentration of growth hormones appeared to have significantly risen throughout the study period.


Mod GRF 1-29 & Ipamorelin Blend and Growth Hormone Deficiency

After 2001, there have been several rigorous clinical studies(7) conducted on subjects with growth hormone deficiency. The studies conducted so far have suggested that:

  1. These peptides may stimulate the pituitary gland to release growth hormones naturally, or
  2. These peptides may act on the arcuate nucleus of the hypothalamus, which may trigger the secretion of growth hormones.

As per Rogerio G Gondo et al., “The predominant site of action of GHSs on GH secretion has not been established. As receptors for GHSs have been identified in both pituitary and hypothalamus (24–26), it is possible that GHSs act at either or both sites.” (7) Besides this suggested growth hormone release, these peptides may also increase food appetite, improve cardiac tone, and help regulate sleep. In another study,(8) six test subjects with growth hormone deficiency were presented a graded concentration of growth hormone secretagogues for eight months. All subjects were monitored for episodic growth hormone secretion. Within two months of peptide presence, these subjects appeared to exhibit an exponential spike in the concentration of growth hormones.


Mod GRF 1-29 & Ipamorelin Blend and Heart Rate

In this preliminary study,(9) experimental rats were examined after being introduced to GHRH peptide analogs such as Modified GRF 1-29 peptide. The results suggested that the peptide may improve heart rate and blood pumping ability, especially after myocardial infarction. These studies also indicated that the peptide might promote heart tissue repair and enhance the ejection fraction rate.


Mod GRF 1-29 & Ipamorelin Blend and Sleep Cycles

Researchers(10) have suggested that a significant portion of the growth hormone secretion affects the deep non-REM sleep (NREMS) cycle daily. Administering growth hormone secretagogues such as Ipamorelin and Modified GRF 1-29 peptide appears to improve the NREMS cycle by stimulating growth hormone secretion. As per Ferenc Obal Jr et al., “Mutant and transgenic animals with a defect in GHRHergic activity display permanently reduced NREMS, which cannot be reversed by means of GH supplementation. GHRH contents and mRNA levels in the hypothalamus correlate with sleep-wake activity during the diurnal cycle and sleep deprivation and recovery sleep. Stimulation of NREMS by GHRH is a hypothalamic action. GABAergic neurons in the anterior hypothalamus/preoptic region are candidates for mediating promotion of NREMS by GHRH.” 


Mod GRF 1-29 & Ipamorelin Blend peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.


  1. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 91976842, CJC1295 Without DAC.
  2. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9831659, Ipamorelin.
  3. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8. doi: 10.1210/en.2004-1286. Epub 2005 Apr 7. PMID: 15817669.
  4. Sigalos, John T, and Alexander W Pastuszak. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews vol. 6,1 (2018): 45-53. doi:10.1016/j.sxmr.2017.02.004
  5. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
  6. Gobburu, J.V.S., Agersø, H., Jusko, W.J. et al. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharm Res 16, 1412–1416 (1999).
  7. Rogério G. Gondo, Manuel H. Aguiar-Oliveira, César Y. Hayashida, Sergio P. A. Toledo, Neusa Abelin, Michael A. Levine, Cyril Y. Bowers, Anita H. O. Souza, Rossana M. C. Pereira, Norma L. Santos, Roberto Salvatori, Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor, The Journal of Clinical Endocrinology & Metabolism, Volume 86, Issue 7, 1 July 2001, Pages 3279–3283,
  8. Mericq V, Cassorla F, Salazar T, Avila A, Iñiguez G, Bowers CY, Merriam GR. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab. 1998 Jul;83(7):2355-60. doi: 10.1210/jcem.83.7.4969. PMID: 9661608.
  9. Schally AV, Zhang X, Cai R, Hare JM, Granata R, Bartoli M. Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists. Endocrinology. 2019 Jul 1;160(7):1600-1612.
  10. Obal F Jr, Krueger JM. GHRH and sleep. Sleep Med Rev. 2004 Oct;8(5):367-77. doi: 10.1016/j.smrv.2004.03.005. PMID: 15336237.

NOTE: These products are intended for laboratory research use only. CJC-1295 NO DAC / MOD GRF 1 29 peptide is not intended for personal use. Please review our Terms and Conditions before ordering.

You may also like…